Показать сокращенную информацию
dc.contributor.author | Yakovlev I. | |
dc.contributor.author | Deev R. | |
dc.contributor.author | Rizvanov A. | |
dc.contributor.author | Isaev A. | |
dc.date.accessioned | 2018-09-19T23:00:00Z | |
dc.date.available | 2018-09-19T23:00:00Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 2191-1630 | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/145896 | |
dc.description.abstract | © 2016, Springer Science+Business Media New York.Due to lack of effective therapies, muscular dystrophies became a focus for gene therapy. Multiple pre-clinical studies have shown successful restoration of dystrofin and dysferlin by RNA editing both in vivo and in vitro, but possibility of a clinical translation is still obscure. A number of new chemicals are being studied, and a search for new techniques is ongoing. This work is intended to give a brief overview of the current state of the RNA editing for treating muscular dystrophies. | |
dc.relation.ispartofseries | BioNanoScience | |
dc.subject | Duchenne muscular dystrophy | |
dc.subject | Dysferlinopathy | |
dc.subject | Exon skipping | |
dc.subject | RNA editing | |
dc.subject | Trans-splicing | |
dc.title | RNA Editing for Muscular Dystrophy Therapy | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 2 | |
dc.relation.ispartofseries-volume | 7 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 386 | |
dc.source.id | SCOPUS21911630-2017-7-2-SID85019131481 |